News - Takeda Pharmaceuticals

Filter

Current filters:

Takeda Pharmaceuticals

Popular Filters

40 to 64 of 192 results

US Priority Review for Takeda's vedolizumab for ulcerative colitis

05-09-2013

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) says that the US Food and Drug Administration…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Santhera regains Catena European rights

04-09-2013

Switzerland-based Santhera Pharmaceuticals (SIX: SANN) says that it has reached an agreement with Takeda…

CatenaEuropeLicensingPharmaceuticalRare diseasesSanthera PharmaceuticalsTakeda Pharmaceuticals

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Takeda further expands presence in Latin America

23-08-2013

Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502), through its Switzerland-based international…

Markets & MarketingPharmaceuticalSouth AmericaTakeda Pharmaceuticals

Takeda's vedolizumab shows efficacy in colitis and Crohn's disease

22-08-2013

A new investigational antibody - vedolizumab - from Japan's largest drugmaker, Takeda Pharmaceuticals…

Gastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Takeda gains first European approval for lurasidone

14-08-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Lundbeck/Takeda's Brintellix has blockbuster potential

02-08-2013

Denmark CNS drug specialist Lundbeck (LUND: CO) and partner Japanese drug major Takeda Pharmaceutical's…

BrintellixedivoxetineEli LillyFetzimaForest LaboratoriesGenericsGlobalLundbeckMarkets & MarketingNeurologicalPharmaceuticalPierre FabreTakeda Pharmaceuticals

Top-line financials for Japanese drug majors

01-08-2013

Among a flurry of first-quarter fiscal 2013/14 financial results released by Japanese drug majors, the…

Dainippon Sumitomo PharmaEisaiFinancialMitsubishi TanabePharmaceuticalTakeda Pharmaceuticals

Takeda gains Chinese approval for diabetes drug

31-07-2013

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

Disappointment for Takeda as Ph III prostate cancer trial fails

29-07-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) has unblinded a Phase III study after analysis showed…

Asia-PacificMen's HealthOncologyorteronelPharmaceuticalResearchTakeda Pharmaceuticals

Three of Takeda's diabetes therapies get positive opinion from EMA unit

29-07-2013

Japan's largest drugmaker Takeda (TSE: 4502) has received a positive opinion from the European Medicines…

DiabetesEuropeIncresyncPharmaceuticalRegulationTakeda PharmaceuticalsVipdometVipidia

Evolution of Japan's pharma wholesalers - by P Reed Maurer

03-07-2013

Half of the definition for evolution (noun; a gradual process in which something changes especially into…

Asia-PacificFinancialMitsubishi TanabePharmaceuticalProductionSankyoShionogiTakeda Pharmaceuticals

$10 million milestone for Sucampo, as Takeda starts US selling of Amitiza for OIC

27-06-2013

USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) says that it has received a $10 million milestone payment…

AmitizaFinancialGastro-intestinalsMarkets & MarketingNorth AmericaPharmaceuticalSucampoTakeda Pharmaceuticals

Takeda files BLA for vedolizumab for Crohn's and ulcerative colitis in USA

21-06-2013

The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a Biologics…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA

20-06-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that its new diabetes products Nesina…

DiabetesKazanoMarkets & MarketingNesinaNorth AmericaOseniPharmaceuticalTakeda Pharmaceuticals

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso

10-06-2013

French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Is the diabetes market facing a blockbuster-free future?

23-05-2013

Japanese drug major Takeda's (TYO: 4502) recently announced positive late-stage results for new type…

DiabetesfasiglifamMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceuticals

Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study

20-05-2013

Danish CNS specialist Lundbeck (LUND: DC) and partner Takeda Pharmaceutical (TYO: 4502), Japan's largest…

BrintellixLundbeckNeurologicalPharmaceuticalResearchTakeda Pharmaceuticalsvortioxetine

Top-line financial results from Japanese drug majors

09-05-2013

Among a batch of Japanese drug majors presenting fiscal year 2013 (ended April 2013) financial results,…

Dainippon Sumitomo PharmaFinancialMitsubishi TanabePharmaceuticalShionogiTakeda Pharmaceuticals

Takeda to acquire Inviragen, gaining rights to promising vaccines

09-05-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a definitive agreement to…

DENVaxInviragenMergers & AcquisitionsPharmaceuticalTakeda PharmaceuticalsVaccines

US Judge throws out verdict in Takeda Actos case

03-05-2013

The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

40 to 64 of 192 results

Back to top